MedTrace Logo

Safety and Efficacy of a Probiotic Supplement in IBS-D

NCT05754177 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-03-06

No results posted yet for this study

Summary

This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).

Conditions

  • Irritable Bowel Syndrome With Diarrhea
  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Probiotic

Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days

OTHER

Placebo

Participants in this arm will receive an equivalent placebo for 84 days.

Sponsors & Collaborators

  • Vizera d.o.o.

    collaborator INDUSTRY

  • The Archer-Daniels-Midland Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754177 on ClinicalTrials.gov